Literature DB >> 30324219

Awakening the "guardian of genome": reactivation of mutant p53.

Akshay Binayke1, Sarthak Mishra1, Prabhat Suman1, Suman Das1, Harish Chander2.   

Abstract

The role of tumor suppressor protein p53 is undeniable in the suppression of cancer upon oncogenic stress. It induces diverse conditions such as cell-cycle arrest, cell death, and senescence to protect the cell from carcinogenesis. The rate of mutations in p53 gene nearly accounts for 50% of the human cancers. Upon mutations, the conformation gets altered and becomes non-native. Mutant p53 displays long half-life and accumulates in the nucleus and interacts with oncoproteins to promote carcinogenesis and these interactions present a formidable challenge for clinicians in therapy of the disease. Variety of approaches have been developed, through which native-like function of p53 can be restored, such as restoration of the native-like structure of p53, activating the p53 family members, etc. Modern scientific techniques have led to the discovery of a variety of molecules to reactivate mutant p53 and restore its transcriptional activity. These compounds include small molecules, various peptides, and phytochemicals. In this review article, we comprehensively discuss these molecules to reactivate mutant p53 to restore the normal function with a particular focus on molecular mechanisms.

Entities:  

Keywords:  Cancer therapy; Drug target; Gain-of-function; Mutant p53; Reactivation

Mesh:

Substances:

Year:  2018        PMID: 30324219     DOI: 10.1007/s00280-018-3701-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

Review 1.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

2.  bcl-2 and p53 as novel biomarkers for predicting malignant transformation in chronic osteomyelitis.

Authors:  Hans Kristian Nugraha; I Gede Eka Wiratnaya; Putu Astawa; I Wayan Juli Sumadi
Journal:  Musculoskelet Surg       Date:  2022-01-07

3.  Serum TP53 Protein Level as a Sensitive Biomarker for the Diagnosis of Myocardial Damage in Children.

Authors:  Xianglin Zeng; Chunwang Lin; Yanna Sun; Jianping Zhang
Journal:  Med Sci Monit       Date:  2022-06-25

4.  Transcription Factor p53 Suppresses Tumor Growth by Prompting Pyroptosis in Non-Small-Cell Lung Cancer.

Authors:  Tianze Zhang; Yongchao Li; Ruidong Zhu; Pengcheng Song; Youlei Wei; Tian Liang; Guangquan Xu
Journal:  Oxid Med Cell Longev       Date:  2019-10-13       Impact factor: 6.543

5.  Regulation of P53 signaling in breast cancer by the E3 ubiquitin ligase RNF187.

Authors:  Xin Li; Zhiguo Niu; Chen Sun; Shu Zhuo; Huijie Yang; Xiao Yang; Yun Liu; Cheng Yan; Zhongbo Li; Qi Cao; Guimei Ji; Yinlu Ding; Ting Zhuang; Jian Zhu
Journal:  Cell Death Dis       Date:  2022-02-14       Impact factor: 9.685

6.  Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.

Authors:  Richard J Kraus; Blue-Leaf A Cordes; Saraniya Sathiamoorthi; Parita Patel; Xueying Yuan; Tawin Iempridee; Xianming Yu; Denis L Lee; Paul F Lambert; Janet E Mertz
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

Review 7.  From cancer to rejuvenation: incomplete regeneration as the missing link (part II: rejuvenation circle).

Authors:  Mamuka G Baramiya; Eugene Baranov; Irina Saburina; Lev Salnikov
Journal:  Future Sci OA       Date:  2020-06-30

Review 8.  P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.

Authors:  Arjelle Decasa Agupitan; Paul Neeson; Scott Williams; Jason Howitt; Sue Haupt; Ygal Haupt
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

Review 9.  p53 signaling in cancer progression and therapy.

Authors:  Hany E Marei; Asmaa Althani; Nahla Afifi; Anwarul Hasan; Thomas Caceci; Giacomo Pozzoli; Andrea Morrione; Antonio Giordano; Carlo Cenciarelli
Journal:  Cancer Cell Int       Date:  2021-12-24       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.